logo-loader
viewCo-Diagnostics

Co-Diagnostics secures $4.2M for coronavirus detection test; shares jump pre-market

It has struck agreements with institutional investors to purchase 470,000 shares of its common stock at $9 per share

Co-Diagnostics - Co-Diagnostics Inc to raise $4.2 million to fund manufacturing of its coronavirus detection tests
Following the news, the company’s stock jumped 58% to $14.10 a share in pre-market trading

Co-Diagnostics Inc (NASDAQ:CODX) announced Thursday a financing plan expected to raise about $4.2 million as it sells its coronavirus detection tests. 

Following the news, the company’s stock jumped 58% to $14.10 a share in pre-market trading. The stock closed up 106% on Thursday. 

Under the registered direct offering priced at-the-market under Nasdaq rules, the company has struck agreements with institutional investors to purchase 470,000 shares of its common stock at $9 per share. It’s expected to close on March 2. 

READ: Co-Diagnostics wins CE Mark and right to market coronavirus detection test across Europe

Co-Diagnostics intends to use the net proceeds for the acquisition of PCR (polymerase chain reaction) equipment and raw materials to be used in connection with the sale of tests used to diagnose infectious disease, including strains and mutations of coronavirus, as well as research and development costs associated with test development for additional pathogens and test menu expansion, and for working capital and other general corporate purposes.

HC Wainwright & Co is acting as the exclusive lead placement agent for the offering. Maxim Group LLC is acting as co-placement agent.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Co-Diagnostics

Price: 9.15 USD

NASDAQ:CODX
Market: NASDAQ
Market Cap: $227.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Co-Diagnostics named herein, including the promotion by the Company of Co-Diagnostics in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Co-Diagnostics expects to win a CE mark-validated...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the Utah-based company expects to achieve a CE mark validation on its coronavirus detection test from the European Union by as early as next week. Egan says the company is very enthused by the entire process of the development...

on 02/21/2020

2 min read